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A B S T R A C T
The Notch pathway is involved in cell proliferation, differentiation and survival. The Notch signaling pathway
is one of the most commonly activated signaling pathways in cancer. Alterations include activating mu-
tations and ampliﬁcation of the Notch pathway, which play key roles in the progression of cancer.
Accumulating evidence suggests that the pharmacological inhibition of this pathway can overcome che-
moresistance. Efforts have been taken to develop Notch inhibitors as a single agent or in combination
with clinically used chemotherapeutics to treat cancer. Some Notch inhibitors have been demonstrated
to have therapeutic eﬃcacy in preclinical studies. This review summarizes the recent studies and clin-
ical evaluations of the Notch inhibitors in cancer.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The Notch signaling cascade is critical for cell proliferation,
differentiation, development and homeostasis [1]. Deregulated Notch
signaling is found in various diseases, such as T-cell leukemia, breast
cancer, prostate cancer, colorectal cancer and lung cancer as well as
central nervous system (CNS) malignancies [2]. Recent evidence has
demonstrated that Notch signaling is associated with esophageal and
breast cancer stem cells [3,4]. Clinically oriented studies have further
highlighted that Notch signaling impacts survival in human cancer [5].
Upon ligand binding, Notch receptors undertake two cleavage
processes mediated by a member of a disintegrin and
metalloproteases (ADAM) family and gamma-secretase, leading to
the release of the Notch intracellular domain (NICD). As a result, it
activates the transcriptional complex. Several small molecule in-
hibitors targeting the Notch pathway, including gamma-secretase
inhibitor (GSI), siRNA and monoclonal antibodies (mAb) against
Notch receptors and Notch ligands, have been developed and are
currently in the clinical trials. Furthermore, Notch inhibitors have
been tested in combination with conventional cytostatic agents or
targeted drugs in phase I or phase II evaluations [6].
Notch signaling pathway
Notch signaling is activated when a ligand binds to a Notch recep-
tor. Inmammals, there are four receptors, Notches 1~4, and ﬁve ligands,
delta-like ligand 1 (DLL1), delta-like ligand 3 (DLL3), delta-like ligand
4 (DLL4), Jagged-1 (JAG1) and Jagged-2 (JAG2) [7]. The Notch recep-
tors express on the surface of cellmembrane,where they canbe cleaved
by a member of a disintegrin andmetalloproteinase family (ADAM17
or ADAM10) of proteases and a presenilin-dependent gamma secretase
complex. As a result, the Notch Intracellular Domain (NICD) is re-
leased and then translocates into the nucleus [8]. In the nucleus, NICD
interacts with the ubiquitous transcription factor CBF-1/suppressor of
hairless/Lag1 (CSL). CSL is a transcriptional repressor that can bind to
the consensus DNA sequence in associationwith a SMART complex in
the absenceof NICD, and results in gene transcriptional activation,which
is involved in two target genes family Hes (Hairy Enhance of Split) and
Hey (Hairy/Enhancer of Spit related with YRPWmotif). Notch signal-
ing regulates p27cip1/waf1, cyclinD1, c-Myc, p21, Survivin, Slug and
Nanog, and also activates the nuclear factor-kappa B (NF-κB) pathway
(Fig. 1) [9]. DLL4-Notch signaling was found to play a key role in liver
metastasis of human small cell lung cancer (SCLC) by regulating nuclear
factor-kappa B (NF-κB) signaling [10] (Table 1).
Notch signaling is demonstrated to play an important role in
embryo development through regulation of cell proliferation, dif-
ferentiation and apoptosis. During mammalian heart development,
Notch signaling is implicated in the maturation of arterial and ven-
tricular cardiomyocytes and the development of the endocardium.
In mouse models, Notch knockout can cause lethal cardiac defects,
including ventricular septum defects, valve defects and cardiomy-
opathy [19]. Moreover, Notch signaling regulates stem cell
differentiation and self-renewal. Loss of Bmil, a downstream target
of Notch signaling, decreases murine intestinal stem cell prolifer-
ation and conversely increases differentiation to goblet cells [20].
However, during development, inhibition of the Notch pathway
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promotes differentiation of the somatic cells and enables routine
generation of human induced pluripotent stem cells (iPSCs) without
non-core pluripotency factors KLF4 and c-Myc via suppressing p21
in a p53-independent manner in mouse and human keratinocytes
[21].
Overwhelming evidence indicates that Notch signaling plays key
roles in carcinogenesis and tumor progression, such as T-cell leu-
kemia and breast cancer [16,22]. Notch1 signalingmediated hypoxia/
HIF-1α induces cell proliferation, invasion and chemoresistance in
T-cell acute lymphoblastic leukemia (T-ALL) [13]. Notch signaling
is also involved in the establishment of mesenchymal phenotype
during tumor progression andmetastasis [23]. The role of Notch sig-
naling in epithelial–mesenchymal transition (EMT) was ﬁrst
unraveled in cardiac valve and cushion formation during heart de-
velopment, through downregulation of epithelial markers and
upregulation of mesenchymal markers [24,25]. Over-expression of
Jagged1was found to reduce E-cadherin expression in human kidney
epithelial cells, suggesting that Notch signaling plays quintessen-
tial roles in EMT [26]. In addition, the inhibition of Notch signaling
by GSI reverses the EMT process [27]. Subsequently, Notch signal-
ing was found to drive stemness in esophageal adenocarcinoma [3].
However, Notch signaling can be tumor suppressive in some cel-
lular contexts, for instance, causing growth arrest by suppressing
SIRT1 and activating p53 in Ewing sarcoma, which is also impli-
cated in B-cell tumors and human keratinocytes [28].
During cancer progression, activating mutations occurred within
and upstream of the PEST domains of Notch1, Notch2 and Notch3
Fig. 1. Diagram of Notch receptor activation and therapeutic target in clinical development. Notch signaling is initiated by ligand binding to Notch receptor, which under-
goes a two-step proteolytic cleavage by ADAM family proteases and γ-secretase, releasing the Notch Intracellular Domain (NICD). The NICD translocates to the nucleus where
it binds to CSL and converts the complex from a repressor to an activator of Notch target genes. Notch signaling could be inhibited by two major classes of Notch inhibitors:
γ-secretase inhibitors and monoclonal antibodies directing against Notch receptors or ligands. Abbreviations: NEC, Notch extracellular subunit; NTM, Notch transmem-
brane fragment; NEXT, Notch extracellular truncated; CSL, C protein binding factor 1/Suppressor of Hairless/Lag-1; NICD, Notch Intracellular Domain.
Table 1
Signiﬁcance of Notch pathway in cancer.
Function Ref
Ligands
DLL 1 Governing cell fate decisions and cell-to-cell
communication
[7]
DLL 3 Suppressing cell growth by apoptosis induction [11]
DLL 4 Activating NF-κΒ signaling to enhance VEGF
secretion and promote metastasis
[10,12]
JAG 1 JAG 1 activation of Notch enhances angiogenesis [7]
JAG 2 Interaction with Notch2 to promote cell survival
and proliferation
[7]
Receptors
Notch1 Transmembrane receptor involved in cell
proliferation, invasion and chemoresistance
[5,13,14]
Notch2 Constitutive Notch2 signaling induces hepatic
tumors
[15]
Notch3 Promoting proliferation and migration, and
modifying chemotherapy response
[11]
Notch4 Involved in endocrine therapy resistance and
EMT in breast cancer
[16]
Targeted genes
Hes1 Sequence-speciﬁc DNA binding transcriptional
factor involved in cellular proliferation and
differentiation
[11,17]
Hey1 Hes-related transcriptional factor involved in
neoplastic vasculature development
[18]
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receptors via several genetic mechanisms and reduced the func-
tion of the PEST domain, which was a negative regulator of the Notch
signaling [29]. In addition, ampliﬁcation of wild-type Notch recep-
tors and ligands is also observed in various tumors. For instance,
Notch1 activating mutation could be identiﬁed in over 50% of T-ALL
tumors [30–32]. However, Notch4 and Notch ligands genes were
mutated at low incidences [33]. Mutations and ampliﬁcations of the
Notch signaling often increased the expression of canonical Notch
target genes, resulting in the progression of cancer. Notch1 rear-
rangements related to high N1-ICD levels in triple-negative breast
cancer xenografts correlatedwith responsiveness to GSI-based thera-
pies. Deregulation of Notch signaling was further identiﬁed in other
cancers [11,34,35]. In a transgenic mouse model, activated Notch1
was overexpressed in the alveolar epithelium and induced alveo-
lar hyperplasia and pulmonary adenomas through regulating type
II lung epithelial cells [14]. When crossed withmice expressingMYC,
transgenic mice progressed to adenocarcinomas andmetastases, in-
dicating a synergistic effect between Notch1 and other oncogenes.
Considerable studies have shown that Notch signaling is in-
volved in tumor pathologic angiogenesis. Whole transcriptome
sequencing revealed that Hey1, a Notch target, played a fundamen-
tal role in neoplastic vasculature development. Inhibition of Notch
signaling decreased the production of new blood vessels in mice
[18]. Notch1 in connection with VEGF-A has a signiﬁcant prognos-
tic impact, indicating that Notch pathway increased the possibility
of metastasis and poor outcome through regulating tumor angio-
genesis via crosstalk with VEGF-A in lung cancer [5]. In agreement,
blockade of the DLL4-Notch pathway is associated with decreased
angiogenesis and tumor growth in severe combined immunodeﬁ-
ciency (SCID) mice with renal cancer xenografts [12]. Importantly,
combined targeting treatments of DLL4 and vascular endothelial
growth factor (VEGF) signaling pathway resulted in enhanced tumor
growth inhibition and a marked decrease in tumor perfusion. In ad-
dition, the clinical signiﬁcance of Notch signaling has also been
observed in lung cancer and breast cancer [11,36]. By conducting
ameta-analysis, Notch1 and Notch3were correlatedwith tumor pro-
gression and prognosis in NSCLC. Furthermore, patients with DLL3
and Hes1 overexpression had signiﬁcantly poor overall survival (OS),
indicating that Notch signaling may be a biomarker to predict pro-
gression and survival of NSCLC patients. Therefore, targeting Notch
signaling may beneﬁt patients with cancer [11].
Targeting Notch signaling with gamma-secretase inhibitors
(GSIs)
Currently, several classes of Notch inhibitors have been devel-
oped, mainly composed of GSI, siRNA and monoclonal antibodies
against Notch receptors or ligands [37]. In vitro studies show that
γ-secretase inhibitor (GSI) effectively represses cancer stem cells
(CSCs) [38]. In a Kras(G12V)-driven NSCLCs mice model, γ-secretase
inhibitor (GSI) blocked cancer growth by reducing HES1 levels and
phosphorylated ERK [39]. Mechanically, GSI triggers apoptosis of
tumor cells through inhibiting proteasome activity and enhancing
endoplasmic reticulum (ER) stress [40]. Time-course studies suggest
that initial apoptosis events induced by Notch inhibition are the result
of the suppression of proteasome activity, concomitant with en-
hanced ER stress apoptosis signaling and Noxa expression, which
precedes mitochondrial alterations in primary CLL cells [41]. At
present, GSIs are the most extensively explored. The completed clin-
ical trials of GSIs in cancer are shown in Table 2. The chemical
properties and biological activity of GSIs are shown in Table 3.
RO4929097
RO4929097, also known as 2,2-dimethyl-N-[(7S)-
6-oxo-5,7-dihydrobenzo[d][1]benzazepin-7-yl]-N′-(2,2,3,3,3-
pentaﬂuoropropyl) propanediamide, is a novel small-molecular
inhibitor of gamma secretase, which is found to decrease prolifer-
ation and impair the ability to form colonies in human primary
melanoma cell lines. Moreover, RO4929097 affected the tumor for-
mation and tumor growth of human primary melanoma xenografts,
suggesting that RO4929097 suppresses the tumor initiating poten-
tial of cancer cells [49]. RO4929097 is well tolerated [44,50], and
the most common treatment-related adverse events were nausea
(53%), fatigue (41%), and anemia (22%) in patients with advanced
cancer [50]. Preliminary evidence of anti-cancer activity was ob-
served in three of nine recurrent ovarian cancer patients, with
prolonged (≥3 months) stable disease (SD) [51]. Moreover,
RO4929097was also administrated in combinationwith other agents.
In a phase I study, thirty patients with refractory cancer received
RO4929097 in combination with capecitabine, and showed clini-
cal beneﬁt in cervical and colon cancer [46]. RO4929097 in
combination with gemcitabine can also be safely tolerated and
achieved clinical antitumor activity and >4 months stable disease
in pancreas, tracheal, and breast primary cancers [47]. The combi-
nation of RO4929097 and Cediranib, a VEGF receptor tyrosine kinase
inhibitor, showed an antitumor eﬃcacy with prolonged disease sta-
bilization in eleven patients (55%) with advanced solid tumors [52].
Co-administration of RO4929097 and temsirolimus (an mTOR in-
hibitor) increased clearance and reduced exposure to temsirolimus
via a drug–drug interaction in refractory advanced solid tumors [48].
Moreover, RO4929097 signiﬁcantly sensitized the putative breast
cancer stem cells to ionizing radiation and reduced normal T-cell
synthesis of inﬂammatory cytokines, suggesting that Notch pathway
plays an important role in inﬂammatory breast cancer (IBC) stem
cells, and that evaluation of inﬂammatory response may predict the
Table 2
Completed clinical trials of GSIs in cancer.
Treatment Trial type and tumor Enrollment Primary endpoint Therapy effect NCT trial number Ref
MK0752 Phase I; advanced solid tumor 103 MTD 1 CR and 12 SD 00106145 [42]
MK0752 Phase I; normal 30 Notch response signature NA 00803894 NR
MK0752 + docetaxel Phase I/II; breast cancer 30 DLT 11 PR, 9 SD, and 3 PD 00645333 [43]
MK0752 + gemcitabine Phase I/II; pancreatic cancer 44 Safety/MTD NA 01098344 NR
RO4929097 Phase II; renal cell carcinoma 5 Eﬃcacy NA 01141569 NR
RO4929097 Phase II; pancreatic cancer 18 Survival rate 3 SD, 01232829 [44]
RO4929097 Phase II, colorectal cancer 37 Eﬃcacy 6 SD, 01116687 [45]
RO4929097 Phase II; NSCLC 6 Eﬃcacy NR 01193868 NR
RO4929097 Phase I; advanced solid tumor 17 Pharmacokinetics study NR 01218620 NR
RO4929097 Phase I; advanced solid tumor 28 Safety NR 01096355 NR
RO4929097 + capecitabine Phase I; refractory solid tumor 30 MTD 3 PR, 01158274 [46]
RO4929097 + gemcitabine Phase I; advanced solid tumor 18 Safety 1 PR, 3 SD 01145456 [47]
RO4929097 + temsirolimus Phase I; advanced solid tumor 17 Safety 11 SD, 01198184 [48]
Abbreviations: NR, not reported; MTD, maximum tolerated dose; DLT, dose limiting toxicity; NSCLC, non-small cell lung cancer.
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eﬃcacy of Notch inhibitor [53]. Nevertheless, RO4929097 showed
minimal single agent activity in patients with metastatic refracto-
ry colorectal cancer and childhood cancer [45,54]. A pharmacokinetic
study demonstrated that RO4929097 is highly bound with α1-
acid glycoprotein (AAG) in human plasma and that only unbound
RO4929097 had pharmacokinetic activity in patients. It was found
that plasma protein binding levels changed by concomitant drug
which competitively binds to AAG or disease states, and that con-
comitant Hedgehog inhibitor GDC-0449 signiﬁcantly increased
unbound RO4929097 levels and improved RO4929097 in vitroNotch-
inhibitory activity [55].
MRK-003
MRK-003, a γ-secretase inhibitor known as (3′R,6R,9R)-5′-(2,2,2-
triﬂuoroethyl)-2-((E)-3-(4-(triﬂuoromethyl)piperidin-1-yl)prop-
1-en-1-yl)-5,6,7,8,9,10-hexahydrospiro[6,9-methanobenzo[8]
annulene-11,3′-[1,2,5]thiadiazolidine] 1′,1′-dioxide, induced caspase-
dependent apoptosis and inhibited proliferation of multiplemyeloma
and non-Hodgkin’s lymphoma cell lines by reducing the expres-
sion of NICD, Hes1 and c-Myc and up-regulating pAkt [17]. In a
murine orthotopic glioblastoma xenograft model, weekly oral de-
livery of MRK003 resulted in signiﬁcant inhibition of tumor growth,
stem cell marker expression as well as clonogenicity, providing pre-
clinical evidence for the application of MRK003 in malignant brain
cancer patients [56]. Combining MRK-003 with trastuzumab, an
ErbB-2 signaling inhibitor, induced tumor regression and pre-
vented tumor recurrence post-trastuzumab treatment in ErbB-2-
positive breast xenografts. Furthermore, MRK-003 was identiﬁed to
partially reverse trastuzumab resistance in vivo [57]. Notably,
MRK003, combined with gemcitabine, synergistically induced wide-
spread hypoxic necrosis, resulting in prolonged survival of pancreatic
ductal adenocarcinoma (PDA) in the LSL-Kras(G12D)(/+);Pdx-1-
Cre mouse model [58].
Table 3
Chemical properties and biological activity of GSIs.
Drug Formula Chemical structure Target IC50 Ref
RO4929097 C22H20F5N3O3 Gamma-secretase 4 nM [44–55]
MRK-003 C25H31F6N3O2S Gamma-secretase NR [17,56–58]
MK-0752 C21H21ClF2O4S Gamma-secretase 5 nM [42,43,59]
PF03084014 C27H41F2N5O Gamma-secretase 6.2 nM [60–65]
Abbreviation: IC50, half maximal inhibitory concentration.
23X. Yuan et al./Cancer Letters 369 (2015) 20–27
MK-0752
MK-0752, known as 3-[4-(4-chlorophenyl) sulfonyl-4-(2,5-
diﬂuorophenyl)cyclohexyl]propanoic acid, is a potent oral inhibitor
of γ-secretase. In a phase I study involving 103 patients with ad-
vanced solid tumor, preliminary antitumor eﬃcacy was observed
via modulation of Notch gene signature (Table 2) [42]. Treatment
with GSIs MK-0752 in breast cancer reduced stem cell subpopula-
tion in vitro and in human tissues from a clinical trial (Table 2) [43].
In addition, MK-0752 is well-tolerated and effective in children with
refractory or recurrent CNS malignancies, supporting a rational ap-
plication of MK-0752 in children [59]. However, the side effects of
MK-0752 include diarrhea, nausea, vomiting, and fatigue.
PF-03084014
PF-03084014, known as (2S)-2-[[(2S)-6,8-diﬂuoro-1,2,3,4-
tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-
2-methylpropan-2-yl]imidazol-4-yl]pentanamide, induced selective
apoptosis of chronic lymphocytic leukemia cells from Notch mutated
CLL patients, while it exhibited little apoptosis induction of normal
T cells or T cells from Notch-unmutated patients, suggesting that
PF-03084014 targeted CLL patients with Notch activating mutations
[60]. In a preclinical model of T-cell acute lymphoblastic leukemia
(T-ALL), PF-03084014 caused cell growth arrest and enhanced apop-
tosis by inducing cell cycle arrest at the G0–G1 phase [6]. Moreover,
PF-03084014altered endothelial cell tube formation andmammosphere
formation in vitro, and exhibited antitumor and antimetastatic activ-
ity in breast xenograft model [61]. In a patient-derived CRC explant
model with elevated Notch expression, PF-03084014 induced tumor
growth arrest via down-regulation of theNotchpathway [62]. In a phase
I trial, PF-03084014 showed drug tolerability and high rate of re-
sponse in desmoid tumors [63]. When combined with gemcitabine,
PF-03084014 treatment resulted in tumor regression in 3 of 4 pancre-
atic cancer xenograft models via targeting malignant cancer stem
cells. Notably, the combined therapy further showed enhanced eﬃca-
cy in the inhibition of tumor cell proliferation and angiogenesis,
attenuating growth of primary tumor and controlling metastatic
dissemination in a highly aggressive orthotopicmodel [64]. Unlike other
agents in this class, the toxicities of PF-03084014were generally mild
or moderate, including diarrhea, nausea, fatigue, hypophosphatemia,
vomiting, rash, and decreased appetite [65].
Synergistic effect of GSI with chemotherapy, radiotherapy and
other signal transducers
Based on published data from clinical trials, single agents of GSIs
have therapeutic effects in cancers. Mechanically, the inhibitory effect
of GSIs was especially signiﬁcant in CD133 (+) cells, suggesting that
Notch pathway blockade may be a strategy to target cancer stem
cells (CSCs) [66,67]. In addition, Notch inhibition attenuated sphere
formation and xenograft growth of CD44(+) CD24(low+) triple neg-
ative breast cancer initiating stem cells [68]. To achieve the best
curative effect, the combination of GSIs with other therapies has also
been studied.
GSI with chemotherapy drug
In vivo studies showed that Notch inhibitors inhibit tumor growth
and sensitize cancer cells to a variety of chemotherapy drugs [69,70].
The treatment of NSCLC cells with platinum enriched CD133 (+) cells.
The later is cross-resistant to chemotherapy. In these enriched CD133
(+) cells, Notch signaling is activated, and Notch inhibition en-
hanced the anti-tumor effect in transplanted tumors and cancer
patients previously receiving cisplatin treatment [71]. Vincristine
(VCR), an anti-microtubule agent, was also synergized with Notch
inhibitor by augmenting VCR-induced apoptosis in HeLa cells [72].
Importantly, Notch inhibition was also found to sensitize to the tar-
geted therapy [73]. Sorafenib (Nexavar), the exclusive clinically
approved drug for advanced hepatic carcinoma, is a multiple kinase
inhibitor. Inhibition of Notch3 signaling enhanced sorafenib-
induced apoptosis via down-regulation of p21 and up-regulation
of pGSK3βSer9 in HCC cells, suggesting that Notch3 inhibition in-
creased the anti-cancer effect of sorafenib through overcoming drug
resistance [74].
GSI with ionizing radiation
As ionizing radiation and Notch inhibition played key roles in
suppressing tumor vasculature, the potential cooperativity between
Notch inhibitors and ionizing radiation in tumor growth regres-
sion was explored in somatic tumors. In human colorectal carcinoma
xenografts, administration of Notch inhibitors after ionizing radi-
ation resulted in growth arrest, with increased tumor vessel density
but reduced tumor blood ﬂow, which promoted extensive tumor
necrosis [75]. Mechanically, Notch inhibitor induced apoptosis of
cancer cell via the regulation of MAPK and Bcl-2 family proteins,
and that GSI administration blocked Notch-induced radiation re-
sistance [76].
GSIs with other signal transducers
A role for Notch signaling in cancer progression and survival sug-
gests that targeting this pathway alone or in combination with other
pathways represents a promising therapeutic strategy. Since Notch
signaling and janus kinase 2 (JAK2)/signal transducers and activa-
tors of transcription 3 (STAT3) pathways have been shown to
participate in the initiation and progression of pancreatic ductal ad-
enocarcinoma (PDAC), targeting these two pathways simultaneously
through dual treatment of gamma-secretase inhibitor IX (GSI IX)
and JAK2 inhibitor (AG-490) dramatically impaired growth and in-
vasion of human pancreatic cancer cell and attenuated tumor
progression in vivo compared to monotherapy, indicating that com-
bined inhibition of Notch and JAK2/STAT3 pathways exceeded either
agent alone [77]. γ-Secretase inhibitor has been shown to eﬃcient-
ly induce apoptosis via induction of Noxa, a pro-apoptotic Bcl2-
homology 3 domain (BH3)-only protein of the Bcl-2 family. The
biologic effects of γ-secretase inhibitor GSIXII combined with BH3-
mimetic inhibitor of antiapoptotic proteins Bcl-2/Bcl-xL (i.e., ABT-
737) have been evaluated. This study showed a synergistic apoptotic
response [78]. Interestingly, in a gastric cancer xenograft model, com-
bined treatment of extracellular signal-regulated kinase (ERK)
inhibitor PD98059 and Notch inhibitor induced additive anti-
cancer effects than a single inhibitor [79]. Moreover, the combination
treatment of the γ-secretase inhibitor compound E, proteasome in-
hibitor bortezomib and histone deacetylase inhibitor romidepsin
signiﬁcantly inhibited tumor growth and prolonged survival in a
murine model of human ATL, compared with all other treatment
groups [80].
Other inhibitors of Notch signaling
In addition, other receptor-speciﬁc approaches can reduce the
invasion of cancer, for instance, siRNA-mediated inhibition of Notch1
has been found to induce tumor growth arrest through nanoparticle
encapsulation [81]. Furthermore, monoclonal antibodies against
Notch signaling have also been developed [82,83]. MEDI0639, an
antibody targeting DLL4 that inhibits the binding of DLL4 to Notch1,
was found to promote human umbilical vein endothelial cell growth
and human vessel formation [84]. In addition, γ-secretase, a trans-
membrane protease that is composed of four subunits encoded by
four genes, PSEN1, PSENEN, NCSTN and APH1, can be inhibited using
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speciﬁc mAbs targeting NSTN. Importantly, NCSTN can be used as
a molecular marker for the targeted therapy [85].
The natural agents, including curcumin, 3,3′-diindolylmethane
(DIM), resveratrol, 3,5-bis(2,4-diﬂuorobenzylidene)-4-piperidone
(DiFiD) and epigallocatechin-3-gallate (EGCG), have been re-
ported to be alternative strategies for the treatment of cancer via
repressing Notch signaling [86,87]. Honokiol, a traditional Chinese
medicine, was also found to increase the sensitivity of colon cancer
stem cells to ionizing radiation (IR) via suppression of activated Notch
signaling. Furthermore, the combination of honokiol and IR sig-
niﬁcantly suppressed tumor xenograft growth, which was coupled
with reduced expression of cancer stem cell marker and Notch sig-
naling in xenograft tissues, suggesting that honokiol is a potent
inhibitor of cancer growth that targets the stem cells by inhibiting
the Notch signaling pathway [88].
Furthermore, inhibitors of aspartate β-hydroxylase (ASPH), a cell
surface protein that catalyzes the hydroxylation of epidermal growth
factor (EGF)-like repeats in Notch receptors and ligands, were de-
veloped and discovered to reduce prostate cancer growth by a
process that relies on the downregulation of the Notch signaling
pathway [89]. In addition, the activation of Notch signaling in-
volves the process of Notch receptor endocytosis toward acidic
compartments, which required vacuolar H(+) ATPase (V-ATPase) for
acidiﬁcation of endocytic organelles. Inhibition of V-ATPase reduced
growth of breast cancer cells via downregulation of Notch signal-
ing [90].
Conclusion
Notch signaling is a conserved cell fate determining factor in
embryo development. However, the deregulation of Notch signal-
ing is frequently observed in many cancers through mutations and
ampliﬁcation of the components of the Notch signaling pathway.
In addition, transgenic mice with liver-speciﬁc activation of Notch2
are suﬃcient to induce HCC formation and biliary hyperplasia [15].
This provides an opportunity for the development of targeted
therapy. Ample evidence has demonstrated that inhibition of Notch
induces tumor growth arrest. Moreover, combined therapy of che-
motherapy or radiotherapy with Notch inhibitors also results in a
synergistic effect, suggesting Notch inhibitors may improve che-
motherapy response. Finally, based on the stratiﬁcation of patients
by Notch activating mutation and ampliﬁcation, Notch inhibitors
combined with chemotherapy or radiotherapy hold great promise
for cancer control.
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